Improving patient clinical outcomes necessitates the exploration and implementation of innovative treatment modalities. Migrastatic-applied therapy (MAT) and photoactivated therapies (PAT) present a promising approach due to their minimal systemic toxicity and broad application spectrum. Designed as mitochondrial probes, polymethinium salts (PMS) exhibit excelent qualities as stable fluorescence, high mitochondria specifity, rapid cellular uptake and great photostability. Our previous work has established the efficacy of first-generation PMS (fgPMS) in targeting mitochondrial function to inhibit cell motility, highlighting the potential of mitochondrial targeting in MAT, however the specific molecular mechanism underlying this effect remains unknown. Furthermore, PMS's unique photochemical properties, including a broad absorption spectral range, position them as ideal candidates for dual therapeutic action, targeting systemic malignancies and chronic inflammations.

Cíle udržitelného rozvoje

Masarykova univerzita se hlásí k cílům udržitelného rozvoje OSN, jejichž záměrem je do roku 2030 zlepšit podmínky a kvalitu života na naší planetě.